# Bevacizumab in Extensive Small Cell Lung Cancer

> **NCT00930891** · PHASE2,PHASE3 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 143 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Standard Chemotherapy (PCDE or PE)
- **DRUG:** Experimental Treatment (PCDE or PE + bevacizumab)
- **DRUG:** Prerandomization Chemotherapy (PCDE or PE)

## Key facts

- **NCT ID:** NCT00930891
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-07
- **Final completion:** 2013-07
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00930891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00930891, "Bevacizumab in Extensive Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00930891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*